Actavis generic prostate cancer drug Bicalutamide first to market in UK, Germany, France

actavis.jpgReykjavik, Iceland, 10 July 2008 — Actavis Group, the international generic pharmaceuticals company, today announced the launch of Bicalutamide tablets in the United Kingdom, Germany and France. Bicalutamide Actavis is the first generic version of the oncology drug to be made available in the three markets.

Bicalutamide, the generic version of AstraZeneca’s Casodex®, is used as a treatment for prostate cancer and will be available in tablet form in 50mg doses in all three markets, as well as in 150mg doses in the UK. Bicalutamide Actavis was launched on day one, when the brand product’s patent expired; on 8 July in the UK and 9 July in Germany and France. Distribution of the product will commence immediately.

Commenting on the launch of Bicalutamide, Svend Andersen, Executive Vice President of Western Europe Sales, said: “We are pleased to be the first generic pharmaceutical company to bring this product to the market – creating value for patients at a lower price. Bicalutamide is an important product in Actavis’ portfolio. It is used in treating prostate cancer and also in combination with other treatments of malign diseases, prescribed by both hospitals and general practitioners.”

Actavis was able to launch generic Bicalutamide in some of its countries of operation as early as 2007, including the Czech Republic, Slovakia, Poland and Iceland.

More information about Actavis can be found on the corporate website: www.actavis.com

Enquiries
Actavis Group
Hjördís Árnadóttir
Director, External Communications
Tel: (+354) 535 2300 / 840 7476
E-mail: harnadottir@actavis.com

About Actavis Group
Actavis is one of the world’s leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. Based in Iceland, the company has operations in 40 countries, with 11,000 employees.

Any statements contained in this press release that refer to Actavis’ estimated or anticipated future results or future activities are forward-looking statements which reflect the Company’s current analysis of existing trends, information and plans. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially depending on factors such as the availability of resources, the timing and effect of regulatory actions, the success of new products, the strength of competition, the success of research and development issues, unexpected contract breaches or terminations, exposure to product liability and other lawsuits, the effect of currency fluctuations and other factors.

Be Sociable, Share!